155 related articles for article (PubMed ID: 37486091)
1. Healthcare resource utilization and costs during first salvage therapy for relapsed or refractory acute myeloid leukemia in the United States.
Muffly L; Young C; Feng Q; Nimke D; Pandya BJ
Leuk Lymphoma; 2023; 64(11):1832-1839. PubMed ID: 37486091
[TBL] [Abstract][Full Text] [Related]
2. Economic and Clinical Burden of Acute Myeloid Leukemia Episodes of Care in the United States: A Retrospective Analysis of a Commercial Payer Database.
Pandya BJ; Chen CC; Medeiros BC; McGuiness CB; Wilson SD; Walsh EH; Wade RL
J Manag Care Spec Pharm; 2020 Jul; 26(7):849-859. PubMed ID: 32281456
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib.
Perl AE; Hosono N; Montesinos P; Podoltsev N; Martinelli G; Panoskaltsis N; Recher C; Smith CC; Levis MJ; Strickland S; Röllig C; Groß-Langenhoff M; Chou WC; Lee JH; Yokoyama H; Hasabou N; Lu Q; Tiu RV; Altman JK
Blood Cancer J; 2022 May; 12(5):84. PubMed ID: 35637252
[TBL] [Abstract][Full Text] [Related]
4. The European Medicines Agency Review of Gilteritinib (Xospata) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an FLT3 Mutation.
Tzogani K; Røshol H; Olsen HH; Aas IB; Dalhus ML; Håkonsen GD; Nilssen LS; Lindberg V; Økvist M; Bolstad B; Rogovska I; Karpova N; Enzmann H; Gisselbrecht C; Pignatti F
Oncologist; 2020 Jul; 25(7):e1070-e1076. PubMed ID: 32154636
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of gilteritinib for relapsed/refractory
Pandya BJ; Qi CZ; Garnham A; Yang H; Shah MV; Zeidan AM
J Manag Care Spec Pharm; 2021 Oct; 27(10):1469-1481. PubMed ID: 34595955
[No Abstract] [Full Text] [Related]
6. Gilteritinib or Chemotherapy for Relapsed or Refractory
Perl AE; Martinelli G; Cortes JE; Neubauer A; Berman E; Paolini S; Montesinos P; Baer MR; Larson RA; Ustun C; Fabbiano F; Erba HP; Di Stasi A; Stuart R; Olin R; Kasner M; Ciceri F; Chou WC; Podoltsev N; Recher C; Yokoyama H; Hosono N; Yoon SS; Lee JH; Pardee T; Fathi AT; Liu C; Hasabou N; Liu X; Bahceci E; Levis MJ
N Engl J Med; 2019 Oct; 381(18):1728-1740. PubMed ID: 31665578
[TBL] [Abstract][Full Text] [Related]
7. Gilteritinib for the treatment of relapsed and/or refractory FLT3-mutated acute myeloid leukemia.
McMahon CM; Perl AE
Expert Rev Clin Pharmacol; 2019 Sep; 12(9):841-849. PubMed ID: 31454267
[No Abstract] [Full Text] [Related]
8. Burden of chemotherapy in patients with relapsed/refractory acute myeloid leukemia in the United States: a retrospective claims database study.
Pandya BJ; Chen CC; McGuiness CB; Sullivan L; Feng Q; Walsh E; Borate U
Expert Rev Hematol; 2022 Sep; 15(9):857-866. PubMed ID: 35924860
[TBL] [Abstract][Full Text] [Related]
9. Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a
Ballesta-López O; Solana-Altabella A; Megías-Vericat JE; Martínez-Cuadrón D; Montesinos P
Future Oncol; 2021 Jan; 17(2):215-227. PubMed ID: 32975130
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y
Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594
[TBL] [Abstract][Full Text] [Related]
11. Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real-world, multi-center, matched analysis.
Shimony S; Canaani J; Kugler E; Nachmias B; Ram R; Henig I; Frisch A; Ganzel C; Vainstein V; Moshe Y; Aumann S; Yeshurun M; Ofran Y; Raanani P; Wolach O
Ann Hematol; 2022 Sep; 101(9):2001-2010. PubMed ID: 35739428
[TBL] [Abstract][Full Text] [Related]
12. A budget impact analysis of gilteritinib for the treatment of relapsed or refractory
Pandya BJ; Yang H; Schmeichel C; Qi CZ; Shah MV
J Med Econ; 2021; 24(1):19-28. PubMed ID: 33280474
[TBL] [Abstract][Full Text] [Related]
13. [Pharmacological and clinical profile of gilteritinib (Xospata
Mori M; Hidaka K
Nihon Yakurigaku Zasshi; 2021; 156(1):37-46. PubMed ID: 33390479
[TBL] [Abstract][Full Text] [Related]
14. Venetoclax Plus Gilteritinib for
Daver N; Perl AE; Maly J; Levis M; Ritchie E; Litzow M; McCloskey J; Smith CC; Schiller G; Bradley T; Tiu RV; Naqvi K; Dail M; Brackman D; Siddani S; Wang J; Chyla B; Lee P; Altman JK
J Clin Oncol; 2022 Dec; 40(35):4048-4059. PubMed ID: 35849791
[TBL] [Abstract][Full Text] [Related]
15. Healthcare resource utilization in adult patients with relapsed/refractory FLT3 mutated acute myeloid leukemia: A retrospective chart review from Spain.
Solana-Altabella A; Boluda B; Rodríguez-Veiga R; Cano I; Acuña-Cruz E; Blanco A; Marco-Ayala J; de la Puerta R; Díaz-González Á; Piñana JL; Sanz J; Sempere A; Cervera J; Barragán E; Sargas C; Ballesta-López O; Megías-Vericat JE; Martínez-Cuadrón D; Sanz MÁ; Montesinos P
Eur J Haematol; 2021 May; 106(5):724-733. PubMed ID: 33609315
[TBL] [Abstract][Full Text] [Related]
16. Treatment patterns and healthcare resource utilization in patients with FLT3-mutated and wild-type acute myeloid leukemia: A medical chart study.
Griffin JD; Yang H; Song Y; Kinrich D; Shah MV; Bui CN
Eur J Haematol; 2019 Apr; 102(4):341-350. PubMed ID: 30578743
[TBL] [Abstract][Full Text] [Related]
17. Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib.
Smith CC; Levis MJ; Perl AE; Hill JE; Rosales M; Bahceci E
Blood Adv; 2022 Apr; 6(7):2144-2155. PubMed ID: 35130342
[TBL] [Abstract][Full Text] [Related]
18. The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation-positive relapsed/refractory acute myeloid leukemia.
Altman JK; Perl AE; Hill JE; Rosales M; Bahceci E; Levis MJ
Cancer Med; 2021 Feb; 10(3):797-805. PubMed ID: 33340276
[TBL] [Abstract][Full Text] [Related]
19. Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia.
Solana-Altabella A; Ballesta-López O; Megías-Vericat JE; Martínez-Cuadrón D; Montesinos P
Expert Opin Emerg Drugs; 2022 Mar; 27(1):1-18. PubMed ID: 35076348
[TBL] [Abstract][Full Text] [Related]
20. Gilteritinib: An FMS-like tyrosine kinase 3/AXL tyrosine kinase inhibitor for the treatment of relapsed or refractory acute myeloid leukemia patients.
Reed DR; Sen JM; Pierce EJ; Elsarrag RZ; K Keng M
J Oncol Pharm Pract; 2020 Jul; 26(5):1200-1212. PubMed ID: 32338136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]